Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports

Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2.0 billion, according to the Financial Times. The deal would bolster Gilead's biotech pipeline and is likely to be sector-moving, with potential near-term share movement for Gilead and Ouro as details and terms are finalized.

Analysis

Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2.0 billion, according to the Financial Times. The deal would bolster Gilead's biotech pipeline and is likely to be sector-moving, with potential near-term share movement for Gilead and Ouro as details and terms are finalized.